<DOC>
	<DOC>NCT00990600</DOC>
	<brief_summary>Primary objective of the study is: To verify if simplification of the antiretroviral regimen, measured as the reduction of pill burden alone, may affect adherence rate of patients.</brief_summary>
	<brief_title>QoL and Adherence to One-pill Once-a-day HAART</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>Efavirenz</mesh_term>
	<mesh_term>Emtricitabine</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<criteria>Age &gt; 18 years Informed consent signed Effective ongoing treatment (HIVRNA &lt; 50 copies/ml) for at least three months Being on a stable HAART regimen based either on two possible drug associations: 3TC/FTC + TDF + EFV FTC/TDF (fixed dose combination) + EFV No previous documented virologic failure Childbearing or breastfeeding. Women of childbearing potential will be asked to adopt effective contraceptive methods or behaviours Any ongoing grade 4 laboratory abnormality</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>October 2009</verification_date>
	<keyword>adherence</keyword>
	<keyword>Qol</keyword>
	<keyword>virologic efficacy</keyword>
	<keyword>immunologic efficacy</keyword>
	<keyword>patients' preference</keyword>
	<keyword>once-daily</keyword>
	<keyword>HAART</keyword>
	<keyword>treatment experienced</keyword>
</DOC>